Evolution of plasma vitamin B(12) in patients with solid cancers during curative versus supportive care

INTRODUCTION: The direction of the causal link between solid cancers and elevated plasma vitamin B(12) (B(12)) remains uncertain. METHODS: We retrospectively included patients having two B(12) measurements with a B(12) initially ≥ 1000 ng/l and a solid cancer diagnosed between the measurements. Pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacombe, Valentin, Patsouris, Anne, Delattre, Estelle, Lacout, Carole, Urbanski, Geoffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641499/
https://www.ncbi.nlm.nih.gov/pubmed/34900064
http://dx.doi.org/10.5114/aoms/140974
Descripción
Sumario:INTRODUCTION: The direction of the causal link between solid cancers and elevated plasma vitamin B(12) (B(12)) remains uncertain. METHODS: We retrospectively included patients having two B(12) measurements with a B(12) initially ≥ 1000 ng/l and a solid cancer diagnosed between the measurements. Patients were included in the Curative or Supportive group according to their treatments. RESULTS: B(12) changes over time differed between groups (p = 0.001): +157.4 ng/l/month in the Supportive care group versus –171.6 ng/l/month in the Curative care group. CONCLUSIONS: The decrease of plasma B(12) in cases of curative care could suggest that this B(12) elevation is secondary to solid cancers.

Ejemplares similares